The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients
The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients
复制标题
DOI：
10.1016/j.regpep.2011.03.003
复制
发表时间：
2011-06-07
影响因子：
--
通讯作者：
Jeppesen, Palle Bekker
中科院分区：
文献类型：
--
作者：
Bremholm, Lasse;Hornum, Mads;Jeppesen, Palle Bekker
背景：外源性胰升糖素样肽-2(GLP-2)治疗可改善短肠综合征(SBS)患者的肠道湿重吸收。在健康受试者中，服用GLP-2会增加小肠血流量。目的：探讨GLP-2对不同长度残馀小肠的SBS患者肠系膜血流及心功能的影响。方法：8例SBS患者空肠端端吻合，小肠长度小于200 cm，采用双盲法给予GLP-2、1600 mg皮下注射或等渗盐水。分别于0、30、60min测定血浆GLP-2浓度，并在0~90min用多普勒超声检测肠系膜上动脉(SMA)和腹腔动脉(CA)的血流量，用连续阻抗心动图和手指容积图测定心血管指标。结果：GLP-2组血浆GLP-2浓度显著升高，而安慰剂组无明显变化。与基线相比，GLP-2 SC下降19.4%(p
Background: Exogenous Glucagon-Like Peptide-2 (GLP-2) treatment improves intestinal wet weight absorption in short bowel syndrome (SBS) patients. In healthy subjects, administration of GLP-2 increases small intestinal blood flow. The aim of the study was to evaluate the effect of GLP-2 on mesenteric blood flow and dynamic changes in cardiac parameters in SBS patients with jejunostomy and varying length of remnant small intestine.Methods: 8 SBS patients with end-jejunostomy and less than 200 cm small intestine were given GLP-2, 1600 mu g subcutaneously (SC), or isotonic saline in a double blinded manner. At 0,30 and 60 min plasma GLP-2 was measured, and from 0 to 90 min, blood flow in the superior mesenteric artery (SMA) and the celiac artery (CA) was measured using Doppler ultrasound (US), and cardiovascular variables were measured by continuous impedance cardiography and finger plethysmography.Results: Plasma GLP-2 concentrations increased significantly in the GLP-2 group, whereas no changes were seen in the placebo group. Compared to baseline, GLP-2 SC elicited a 19.4% decrease (p